Abstract Library

#2913 The Predictive Value of Neuroendocrine Transcript Analysis in Daily Practice: An Independent ‘Real-World’ Validation Study

Introduction: Assessment of disease status remains the fundamental basis in the management of gastro-entero-pancreatic neuro-endocrine tumors (GEPNETs). Circulating molecular information might be used as a liquid biopsy to predict its clinical course.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: van Treijen M

Authors: van Treijen M, van der Zee D, Heeres B, Staal F, Vriens M,

Keywords: biomarker, progression-free survival, gastro-entero-pancreatic neuroendocrine tumours,

#2797 Assessment of Quality of Life in Patients with Neuroendocrine Tumours: Results of a Systematic Literature Review

Introduction: Health related quality of life (HRQoL) is increasingly important as a concept reflecting the patients’ perspective in conjunction with the disease presentation severity and treatment. Understanding the impact of treatment on neuroendocrine tumour (NET) patients’ HRQoL is paramount given the nature of the disease.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Fountain D, Leeuwenkamp O, Watson C, Longworth L,

Keywords: Gastro-entero-pancreatic neuroendocrine tumours, Quality of Life, 177Lu-Dotatate, EORTC QLQ-C30,

#2196 The Neuroendocrine Phenotype, Genomic Profile, and Therapeutic Sensitivity of GEPNET Cell Lines

Introduction: Patient tumour-derived cell lines have been widely used for studying the molecular mechanisms of tumours and their response to therapy. The establishment of cell lines from gastro-entero-pancreatic neuroendocrine tumours (GEPNETs) has proved difficult, but despite the challenges a limited amount of cell lines now exists.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Hofving T, Arvidsson Y, Almobarak B, Inge L, Pfragner R,

Keywords: neuroendocrine tumor, GEP-NET, immunophenotyping, copy-number alterations, exome sequencing, inhibitor screening, vorinostat, trametinib,

#1759 Safety and Tolerability of "Ready-to-Use" (SOMAKIT TOC®) 68Ga-DOTA0-Tyr3-Octreotide (68Ga-DOTATOC) for Injection in Patients with Proven Gastro-Entero-Pancreatic Neuroendocrine Tumours (GEP-NETs)

Introduction: 68Ga-DOTATOC (PET) has superior diagnostic performance than Octreoscan (SPECT) in patients with GEP-NETs.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Manoharan P

Authors: Manoharan P, Navalkissoor S, Lamarca A, Calero J, Chan P,

Keywords: SomaKit, DOTATOC, GEP-NET,

#1563 Impact of Early Surgery on Prognosis in Advanced Gastro-entero-pancreatic Neuroendocrine Tumours (GEP-NET)

Introduction: In gastro-entero-pancreatic neuroendocrine tumours (GEP-NET) the role of surgery remains to be determined.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Hammer P, Lipp R, Thalhammer M, Mischinger H, Kornprat P,

Keywords: GEP-NET surgery, medical treatment, prognosis, GEP-NET-registry,